Prima BioMed (IMMP)
(Delayed Data from NSDQ)
$1.89 USD
+0.02 (1.07%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $1.89 0.00 (0.00%) 6:10 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
IMMP 1.89 +0.02(1.07%)
Will IMMP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMMP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMMP
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
Prima BioMed (IMMP) Loses -34.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
IMMP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immutep (IMMP) Up on Initial Data From Lung Cancer Study
Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data
Other News for IMMP
Immutep to Participate in Upcoming Investor Conferences
Immutep Advances LAG-3 Immunotherapy Trials
Immutep Quarterly Activities Report Q4 FY24
Immutep resports quarterly activities for Q4
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session